XML 112 R49.htm IDEA: XBRL DOCUMENT
v3.25.1

Share-based payments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Disclosure of terms and conditions of share-based payment arrangement [abstract] |
Disclosure of number and weighted average remaining contractual life of founders' warrants, warrants, and free shares outstanding | The number of warrants and options outstanding on December 31, 2024 and their main characteristics, are detailed below: Founders’ warrants
| Pre-2024 founders’ warrant plan
|  | BSPCE 09-2014 |  | BSPCE 2015-1 |  | BSPCE 2015-03 |  | BSPCE 2016 Ordinary |  | BSPCE 2016 Performance |  | BSPCE 2017 Ordinary |  | BSPCE 2017
Type of underlying asset |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares
Number of founder’s warrants granted |  | 97,200 |  | 71,650 |  | 53,050 |  | 126,400 |  | 129,250 |  | 117,650 |  | 80,000
Date of shareholders' resolution approving the plan |  | 06/18/2014 |  | 06/18/2014 |  | 06/18/2014 |  | 06/25/2015 |  | 06/25/2015 |  | 06/23/2016 |  | 06/23/2016
Grant date |  | 09/16/2014 |  | 02/10/2015 |  | 06/10/2015 |  | 02/02/2016 |  | 02/02/2016 |  | 01/07/2017 |  | 01/07/2017
Contractual expiration date |  | 09/16/2024 |  | 02/10/2025 |  | 06/10/2025 |  | 02/02/2026 |  | 02/02/2026 |  | 01/07/2027 |  | 01/07/2027
Grant price |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Exercise price |  | €18.68 |  |  | €18.57 |  |  | €20.28 |  |  | €14.46 |  |  | €14.46 |  |  | €15.93 |  |  | €15.93 |
Number of founders’ warrants as of December 31, 2024 |  | — |  | 67,750 |  | 27,350 |  | 96,817 |  | 98,100 |  | 97,050 |  | 80,000
Number of founders’ warrants exercised |  | — |  | — |  | — |  | 333 |  | — |  | — |  | —
Including founders’ warrants exercised during the period |  | — |  | — |  | — |  | — |  | — |  | — |  | —
Number of founders’ warrants lapsed or cancelled |  | 97,200 |  | 3,900 |  | 25,700 |  | 29,250 |  | 31,150 |  | 20,600 |  | —
Including founders’ warrants lapsed or cancelled during the period |  | 85,750 |  | 350 |  | 1,050 |  | 1,050 |  | 1,050 |  | 1,050 |  | —
Warrants (BSA)
|  | Pre-2024 warrant plans
|  | BSA 2014 |  | BSA 2015-1 |  | BSA 2015-2 (a) |  | BSA 2018-2 |  | BSA 2019-1 |  | BSA 2020 |  | BSA 2021 (a)
Type of underlying assets |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares
Number of warrants granted |  | 14,000 |  |  | 26,000 |  |  | 64,000 |  |  | 5,820 |  |  | 18,000 |  |  | 18,000 |  |  | 48,103 |
Date of shareholders' resolution approving the plan |  | 06/18/2014 |  | 06/18/2014 |  | 06/18/2014 |  | 05/23/2018 |  | 05/23/2018 |  | 04/11/2019 |  | 11/30/2020
Grant date |  | 09/16/2014 |  | 02/10/2015 |  | 06/25/2015 |  | 07/27/2018 |  | 03/29/2019 |  | 03/17/2020 |  | 04/20/2021
Contractual expiration date |  | 09/16/2024 |  | 02/10/2025 |  | 06/25/2025 |  | 07/27/2028 |  | 03/29/2029 |  | 03/17/2030 |  | 04/20/2031
Grant price |  | €4.87 |  |  | €4.87 |  |  | €5.00 |  |  | €2.36 |  |  | €1.15 |  |  | €0.29 |  |  | €2.95 |
Exercise price |  | €17.67 |  |  | €17.67 |  |  | €19.54 |  |  | €16.10 |  |  | €11.66 |  |  | €6.59 |  |  | €13.47 |
Number of warrants as of December 31, 2024 |  | — |  |  | 21,000 |  |  | 64,000 |  |  | 5,820 |  |  | 18,000 |  |  | 18,000 |  |  | 14,431 |
Number of warrants exercised |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Including warrants exercised during the period |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Number of warrants lapsed or cancelled |  | 14,000 |  |  | 5,000 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 33,672 |
Including warrants lapsed or cancelled during the period |  | 10,000 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Free shares
|  | Pre-2024 free shares plan vested | Pre-2024 free shares plan not yet vested
|  | AGA 2022 | AGA 2023 - P1 |  | AGA 2023 - P1
Type of underlying assets |  | New shares | New shares |  | New shares
Number of free shares granted |  | 300,039 | 427,110 |  | 439,210
Date of shareholders' resolution approving the plan |  | 04/28/2021 | 06/27/2023 |  | 06/27/2023
Grant date |  | 06/22/2022 | 06/27/2023 |  | 06/27/2023
Grant price |  | — |  | — |  |  | — |
Exercise price |  | — |  | — |  |  | — |
Number of free shares as of December 31, 2024 |  | — | 392,460 |  | 423,460
Number of free shares exercised |  | 293,523 | — |  | —
Including free shares exercised during the period |  | 293,523 | — |  | —
Number of free shares lapsed or cancelled |  | 6,516 | 34,650 |  | 15,750
Including free shares lapsed or cancelled during the period |  | 253 | 8,500 |  | 9,100
|  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Total number of shares underlying grants outstanding as of December 31, 2024 |  | 467,067 |  | 141,251 |  | 3,512,302 |  | 815,920 |  | 4,936,540
|  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Total number of shares underlying grants outstanding as of December 31, 2023 |  | 557,367 |  | 151,251 |  | 2,336,175 |  | 1,127,296 |  | 4,172,089
|  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Total number of shares underlying grants outstanding as of December 31, 2022 |  | 614,726 |  | 185,251 |  | 2,059,523 |  | 653,746 |  | 3,513,246
Disclosure of number and weighted average remaining contractual life of share options outstanding | Stock options
|  | Pre-2024 stock option plans |  |  |  | 2024 stock options plan
|  | OSA 2016-1 Performance |  | OSA 2016-2 |  | OSA 2017 Ordinary |  | OSA 2018 |  | OSA 2019-1 |  | OSA LLY 2019 |  | OSA 2020 |  | OSA 2021-04 |  | OSA 2021-06 |  | OSA 2022-06 Ordinary |  | OSA 2022-06 Performance |  | OSA 2023-01 Ordinary |  | OSA 2024-01 Ordinary
Type of underlying asset |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares |  | New shares
Number of options granted |  | 6,400 |  |  | 4,000 |  |  | 3,500 |  |  | 62,000 |  |  | 37,500 |  |  | 500,000 |  |  | 407,972 |  |  | 571,200 |  |  | 120,000 |  |  | 410,500 |  |  | 170,400 |  |  | 338,860 |  |  | 1,224,780 |
Date of shareholders' resolution approving the plan |  | 06/25/2015 |  | 06/23/2016 |  | 06/23/2016 |  | 06/14/2017 |  | 05/23/2018 |  | 04/11/2019 |  | 04/11/2019 |  | 11/30/2020 |  | 04/28/2021 |  | 04/28/2021 |  | 11/30/2020 |  | 06/27/2023 |  | 05/23/2024
Grant date |  | 02/02/2016 |  | 11/03/2016 |  | 01/07/2017 |  | 03/06/2018 |  | 03/29/2019 |  | 10/24/2019 |  | 03/11/2020 |  | 04/20/2021 |  | 06/21/2021 |  | 06/22/2022 |  | 06/22/2022 |  | 07/20/2023 |  | 05/23/2024
Contractual expiration date |  | 02/02/2026 |  | 11/03/2026 |  | 01/07/2027 |  | 03/06/2028 |  | 03/29/2029 |  | 10/24/2029 |  | 03/11/2030 |  | 04/20/2031 |  | 06/21/2031 |  | 06/22/2032 |  | 06/22/2032 |  | 07/20/2033 |  | 05/23/2034
Grant price |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Exercise price |  | €13.05 |  |  | €14.26 |  |  | €14.97 |  |  | €12.87 |  |  | €11.08 |  |  | €6.41 |  |  | €6.25 |  |  | €13.74 |  |  | €12.99 |  |  | €4.16 |  |  | €4.16 |  |  | €5.00 |  |  | €5.81 |
Number of options as of December 31, 2024 |  | 400 |  |  | 4,000 |  |  | 500 |  |  | 50,000 |  |  | 24,750 |  |  | 500,000 |  |  | 368,707 |  |  | 384,132 |  |  | 120,000 |  |  | 386,333 |  |  | 133,080 |  |  | 318,860 |  |  | 1,221,540 |
Number of options exercised |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Number of options as of Including options exercised during the period |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Number of options lapsed or cancelled |  | 6,000 |  |  | — |  |  | 3,000 |  |  | 12,000 |  |  | 12,750 |  |  | — |  |  | 39,265 |  |  | 187,068 |  |  | — |  |  | 24,167 |  |  | 37,320 |  |  | 20,000 |  |  | 3,240 |
Including options lapsed or cancelled during the period |  | — |  |  | — |  |  | — |  |  | 2,000 |  |  | 1,000 |  |  | — |  |  | 9,068 |  |  | 12,068 |  |  | — |  |  | 8,167 |  |  | 13,110 |  |  | — |  |  | 3,240 |
|  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Total number of shares underlying grants outstanding as of December 31, 2024 |  | 467,067 |  | 141,251 |  | 3,512,302 |  | 815,920 |  | 4,936,540
|  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Total number of shares underlying grants outstanding as of December 31, 2023 |  | 557,367 |  | 151,251 |  | 2,336,175 |  | 1,127,296 |  | 4,172,089
|  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Total number of shares underlying grants outstanding as of December 31, 2022 |  | 614,726 |  | 185,251 |  | 2,059,523 |  | 653,746 |  | 3,513,246
Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period |
BSPCE | Share price (in euros) | Exercise price (in euros) | Volatility | Maturity (in years) | Risk-free rate | Yield | Value of initial plan (in thousands of euros) | Expense for the year ended 2024 (in thousands of euros) | Expense for the year ended 2023 (in thousands of euros) | Expense for the year ended 2022 (in thousands of euros)
BSPCE 09-2014 | 18.68 |  | 18.68 |  | 58 | % | 5.5/6/6.5 | 0.64 | % | 0.00 | % | 965 |  | — |  | — |  | — |
BSPCE 2015-1 | 18.57 |  | 18.57 |  | 58% - 62% - 61% | 5.5/6/6.5 | 0.39 | % | 0.00 | % | 50 |  | — |  | — |  | — |
BSPCE 2015-3 | 20.28 |  | 20.28 |  | 61% - 62% - 61% | 5.5/6/6.5 | 0.56 | % | 0.00 | % | 483 |  | — |  | — |  | — |
BSPCE 2016 Ordinary | 14.46 |  | 14.46 |  | 59% - 62% - 60% | 5.5/6/6.5 | 0.32 | % | 0.00 | % | 1,080 |  | — |  | — |  | — |
BSPCE 2016 Performance | 14.46 |  | 14.46 |  | 59 | % | 5 | 0.19 | % | 0.00 | % | 1,212 |  | — |  | 18 |  | 28 |
BSPCE 2017 Ordinary | 15.93 |  | 15.93 |  | 58% - 61% - 59% | 5.5/6/6.5 | 0.23 | % | 0.00 | % | 1,000 |  | — |  | — |  | — |
BSPCE 2017 Performance | 15.93 |  | 15.93 |  | 59 | % | 5 | 0.11 | % | 0.00 | % | 622 |  | — |  | — |  | — |
BSPCE 2017 | 15.93 |  | 15.93 |  | 59 | % | 5 | 0.11 | % | 0.00 | % | 627 |  | — |  | — |  | — |
BSPCE 2017 Project | 15.93 | 15.93 | 59 | % | 5 | 0.11 | % | 0.00 | % | 94 |  | — |  | — |  | — |
Total BSPCE | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | — |  | 18 |  | 28 |
BSA | Share price (in euros) | Exercise price (in euros) | Volatility | Maturity (in years) | Risk-free rate | Yield | Value of initial plan (in thousands of euros) | Expense for the year ended 2024 (in thousands of euros) | Expense for the year ended 2023 (in thousands of euros) | Expense for the year ended 2022 (in thousands of euros)
BSA 2014 | 18.68 |  | 17.67 |  | 57 | % | 5 | 0.41 | % | 0.00 | % | — |  | — |  | — |  | — |
BSA 2015-1 | 17.67 |  | 17.67 |  | 58 | % | 5 | 0.26% - 0.27% | 0.00 | % | 63 |  | — |  | — |  | — |
BSA 2015-2 a | 19.54 |  | 19.54 |  | 58%-58%-57%-58% | 5/5.1/5.3/5.4 | 0.39 | % | 0.00 | % | 16 |  | — |  | — |  | — |
BSA 2015-2 b | 19.54 |  | 19.54 |  | 58% - 60% | 4.6 – 9.6 | 0.25% - 0.91% | 0.00 | % | 284 |  | — |  | — |  | — |
BSA 2018-2 | 16.10 |  | 16.10 |  | 38 | % | 4.8 | 0.7% - 0.1% | 0.00 | % | 1 |  | — |  | — |  | — |
BSA 2019-1 | 11.66 |  | 11.66 |  | 37 | % | 9.8/9.9 | 0.16% - 0.50% | 0.00 | % | 24 |  | — |  | — |  | — |
BSA 2020 | 6.59 | 6.59 | 38 | % | 10 | (0.13)% - (0.07)% | 0.00 | % | 19 |  | — |  | — |  | — |
BSA 2021 (a) | 13.47 |  | 13.47 | 39.10 | % | 10 | 0.27 | % | 0.00 | % | 44 |  | — |  | — |  | — |
Total BSA | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | — |  | — |  | — |
AGA | Share price (in euros) | Exercise price (in euros) | Volatility | Maturity (in years) | Risk-free rate | Yield | Value of initial plan (in thousands of euros) | Expense for the year ended 2024 (in thousands of euros) | Expense for the year ended 2023 (in thousands of euros) | Expense for the year ended 2022 (in thousands of euros)
AGA 2020 | 5.90 |  | 0.00 |  | n.a. | n.a. | '-0.74%/ -0.69% | 0.00 | % | 287 |  | — |  | — |  | 28 |
AGA 2021 | 13.60 |  | 0.00 |  | n.a. | n.a. | 0.63% 0.59% | 0.00 | % | 4,869 |  | — |  | 694 |  | 2,283 |
AGA 2022 | 3.68 |  | 0.00 |  | n.a. | n.a. | 0.95% 1.46% | 0.00 | % | 1,092 |  | 253 |  | 530 |  | 286 |
AGA 2023 - P1 | 4.87 | 0 | n.a. | n.a. | 3% 3.20% | 0.00 | % | 2,071 |  | 959 |  | 497 |  | — |
AGA 2023 - P2 | 4.87 |  | 0.00 |  | n.a. | n.a. | 3% 3.20% | 0.00 | % | 2,130 |  | 1,040 |  | 543 |  | — |
Total AGA | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 2,252 |  | 2,264 |  | 2,597 |
(in thousands of euros) |  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Expense for the year ended December 31, 2024 |  | — |  | — |  | 2,047 |  | 2,252 |  | 4,298
(in thousands of euros) |  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Expense for the year ended December 31, 2023 |  | 18 |  | — |  | 941 |  | 2,264 |  | 3,222
(in thousands of euros) |  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Expense for the year ended December 31, 2022 |  | 28 |  | — |  | 548 |  | 2,597 |  | 3,173
Disclosure of indirect measurement of fair value of goods or services received, share options granted during period |
OSA | Share price (in euros) | Exercise price (in euros) | Volatility | Maturity (in years) | Risk-free rate | Yield | Value of initial plan (in thousands of euros) | Expense for the year ended 2024 (in thousands of euros) | Expense for the year ended 2023 (in thousands of euros) | Expense for the year ended 2022 (in thousands of euros)
OSA 2016 Ordinary | 13.05 |  | 13.05 |  | 59% - 62% - 60% | 5.5 / 6 /6.5 | 0.32 | % | 0.0 | % | 117 |  | — |  | — |  | — |
OSA 2016 Performance | 13.05 |  | 13.05 |  | 59 | % | 5 | 0.19 | % | 0.0 | % | 69 |  | — |  | — |  | — |
OSA 2016-2 | 14.26 |  | 14.26 |  | 58% - 62% - 59% | 5.5 / 6 /6.5 | 0.04 | % | 0.0 | % | 27 |  | — |  | — |  | — |
OSA 2017 Ordinary | 15.93 |  | 14.97 |  | 58% - 61% - 59% | 5.5 / 6 /6.5 | 0.23 | % | 0.0 | % | 31 |  | — |  | — |  | — |
OSA 2017 Performance | 15.93 |  | 14.97 |  | 59 | % | 5 | 0.11 | % | 0.0 | % | 35 |  | — |  | — |  | — |
OSA 2018 | 12.87 |  | 12.87 |  | 35 | % | 5.5 / 6 /6.5 | 0.00 | % | 0.0 | % | 252 |  | — |  | — |  | — |
OSA 2019-1 | 11.08 |  | 11.08 |  | 38.1% / 37.4% | 6 /6.5 | 0.103% / 0.149% | 0.0 | % | 140 |  | — |  | — |  | (1) |
OSA 2019 LLY | 6.41 |  | 6.41 |  | 37 | % | 10 | 0.40 | % | 0.0 | % | 252 |  | — |  | — |  | — |
OSA 2020 | 6.25 |  | 6.25 |  | 38 | % | 10 | 0.31 | % | 0.0 | % | 939 |  | — |  | 13 |  | 101 |
OSA 2021-04 O | 13.60 |  | 13.74 |  | 38.9% - 37.8% - 38.3% | 5.5 / 6 /6.5 | 0.38%/ 0.33%/ 0.28% | 0.0 | % | 684 |  | 5 |  | 34 |  | (28) |
OSA 2021-04 P | 13.60 |  | 13.74 |  | 39.10 | % | 10 | 0.03 | % | 0.0 | % | 1,816 |  | 226 |  | 216 |  | 163 |
OSA 2021-06 O | 12.20 |  | 12.99 |  | 39.2% / 37.9% / 38.1% | 5.5 6 6.5 | 0.35% 0.30% 0.26% | 0.0 | % | 246 |  | 13 |  | 47 |  | 107 |
OSA 2021-06 P | 12.20 |  | 12.99 |  | 39.10 | % | 10 | 0.13 | % | 0.0 | % | 212 |  | 24 |  | 24 |  | 24 |
OSA 2022-06 O | 3.68 |  | 4.16 |  | 42.06% 41.21% 40.65% | 5.5 / 6/6.5 | 1.83% / 1.87% / 1.90% | 0.0 | % | 580 |  | 86 |  | 267 |  | 178 |
OSA 2022-06 P | 3.68 |  | 4.16 |  | 40.08 | % | 10 | 2.28 | % | 0.0 | % | 80 |  | 11 |  | 20 |  | 4 |
OSA 2023 - 01 O | 6.75 |  | 5.00 |  | 45.07% - 44.11% - 43.41% | 5.55 / 6 / 6.5 | 2.85% / 2.83% / 2.82% | 0.0 | % | 1,255 |  | 544 |  | 321 |  | — |
OSA 2024 - 01 O | 5.19 |  | 5.81 |  | 53.30% / 51.9% / 50.7% | 5.4 / 5.9 / 6.4 | 3.00% / 3.02% / 3.02% | 0.0 | % | 3,107 |  | 1,138 |  | — |  | — |
Total OSA | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 2,047 |  | 941 |  | 548 |
(in thousands of euros) |  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Expense for the year ended December 31, 2024 |  | — |  | — |  | 2,047 |  | 2,252 |  | 4,298
(in thousands of euros) |  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Expense for the year ended December 31, 2023 |  | 18 |  | — |  | 941 |  | 2,264 |  | 3,222
(in thousands of euros) |  | BSPCE |  | BSA |  | OSA |  | AGA |  | Total
Expense for the year ended December 31, 2022 |  | 28 |  | — |  | 548 |  | 2,597 |  | 3,173

X
- Definition The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 47 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 47 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 45 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments + References No definition available. + Details
Name: | nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock
Namespace Prefix: | nbx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration